Deniz Erturk-Hasdemir
Principal scientist - Immunology Ultragenyx Pharmaceutical Inc.
Seminars
Thursday 26th March 2026
Intravenous AAV Gene Therapy Redosing in Mice Treated with Transient B Cell Directed Immunomodulation
3:00 pm
- Transient, B cell directed immunomodulation regimen using anti-mCD20+antimBAFF effectively depleted B cells in the blood
- Anti-mCD20+anti-mBAFF reduced formation of anti-AAV IgM and IgG and allowed liver-directed AAV redosing in a subset of animals
- Redosing was possible using the same AAV gene therapy vector at clinically relevant doses
